SCHEMBL23036946

SCHEMBL23036946

O=Cc1ccn(-c2ccccn2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 2/20 0.56
▸ RPTOR Q8N122 1/20 0.53
▸ MLST8 Q9BVC4 1/20 0.53
▸ GRM5 P41594 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ ALKBH2 Q6NS38 1/20 0.40
▸ EGLN1 Q9GZT9 1/20 0.40
▸ RAB9A P51151 3/20 0.38
▸ GAA P10253 1/20 0.38
▸ GRIA1 P42261 4/20 0.38
▸ CYP1A2 P05177 3/20 0.38
▸ EP300 Q09472 1/20 0.38
▸ KAT2B Q92831 1/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ ATM Q13315 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ KDM5A P29375 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30689214 1.00 MTOR (0.56) MTORRPTORMLST8GRM5SMN1; SMN2
SCHEMBL27905732 0.78 ELOVL1 (0.39) MTORRPTORMLST8
SCHEMBL1907360 0.77 MAPT (0.63) MTORRPTORMLST8GRM5SMN1; SMN2
SCHEMBL38651177 0.77 MAPT (0.63) MTORRPTORMLST8GRM5SMN1; SMN2
SCHEMBL1060286 0.74 P2RX7 (0.56) SMN1; SMN2GAANPC1ATMMAPT
SCHEMBL13933622 0.73 HCAR2 (0.41) MTORRPTORMLST8
SCHEMBL15520187 0.73 GRIA1 (0.40) MTORRPTORMLST8GRIA1
SCHEMBL29563483 0.73 MPO (0.46) MTORRPTORMLST8GRM5SMN1; SMN2
SCHEMBL2643353 0.73 GRM5 (0.46) MTORRPTORMLST8GRM5SMN1; SMN2
SCHEMBL2160327 0.73 MPO (0.46) MTORRPTORMLST8GRM5SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112368279-B Novel compounds as mTOR inhibitors and uses thereof 医药生命融合研究团 2024-05-28 — — CN disclosed
WO-2023250157-A9 INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE CORNELL UNIVERSITY (US) 2024-01-25 — — WO disclosed
WO-2023250157-A1 INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE CORNELL UNIVERSITY (US) 2023-12-28 — — WO disclosed
US-11649231-B2 Compound as mTOR inhibitor and use thereof MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) 2023-05-16 — — US disclosed
US-20210292314-A1 NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) 2021-09-23 — — US disclosed
EP-3786163-A1 NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF Medicinal Bioconvergence Research Center (KR) 2021-03-03 — — EP disclosed
CN-112368279-A Novel compounds as mTOR inhibitors and uses thereof 医药生命融合研究团 2021-02-12 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649231-B2 Compound as mTOR inhibitor and use thereof MTOR, RICTOR, RPTOR MTOR 1/4885RPTOR 3/4885MLST8 8/4885
US-20210292314-A1 NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF MTOR, RICTOR, RPTOR MTOR 1/4885RPTOR 3/4885MLST8 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback